

PACT UPDATE

Production Assistance for Cellular Therapies (PACT) Is Now Accepting Applications

The National Heart, Lung, and Blood Institute (NHLBI) is pleased to announce that the PACT program is now accepting Request for Services Applications (RSAs) from cellular therapy investigators. Interested investigators are able to apply to PACT and submit an RSA for cell therapy manufacturing services. Visit the PACT website at www.pactgroup.net to apply.

PACT Web Seminar – *Accelerating Cell Therapy*

Please join us on Tuesday March 14, 2017 for a free interactive web seminar. An overview of the application process and criteria, and the details surrounding PACT manufacturing assistance will be presented. Representatives from the 5 PACT Cell Processing Facilities will present on their diverse product manufacturing capabilities. Web seminar registration opened February 21, 2017. Visit www.pactgroup.net for details.

About PACT

PACT's objective is to promote the advancement of cellular therapy research on regeneration of damaged/diseased tissues, organs, and biologic systems, and targeted treatments for serious diseases without effective therapies in support of the NHLBI. PACT will support translational research of novel cell therapies that advance the field of cellular therapy. PACT enables scientifically meritorious translational science research to progress along IND-enabling pathways.

Production assistance is provided through the NHLBI-funded contract manufacturing of therapeutic cell products at the 5 designated PACT processing facilities. These facilities offer scale-up capability and expertise in the translational development needed to produce cell therapy products under cGMP/cGLP conditions. PACT's educational training focuses on: translational development/scale-up and manufacture of cell therapy products, and quality assurance and regulatory issues.

Contact:

PACT

The Emmes Corporation, Rockville, MD

Debbie Wood or Laarni Ibenana

phone: 301-251-1161

email: pactinfo@pactgroup.net

This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN268201600020C